contains a peptide derived from human IL-15 to replace amino acid 29-40 in IL-2 (Patent NO. US11897930B2). AWT020 contains two humanized anti-PD-1 nanobodies, a human IgG4 Fc domain, and an IL-2c ...
CSPC PHARMA (01093.HK) announced that JMT108, a new Class I bi-functional fusion protein drug developed by the group, has ...
Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...
Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody <li /> On track ...
Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback